IMMUNOHISTOCHEMICAL BIOMARKERS IN EC 117 5 The DSS according to the ESMO-ESGO-ESTRO risk classification groups, and detailed survival curves of the ESMO-ESGO-ESTRO risk group in relation to the IHC expression were comparable to the RFS (Supplementary Figure S1 A and Figure S2 A-C). Within the ESMO ‘high and advanced/metastatic’ risk group, patients with abnormal IHC expression of; p53, L1CAM and ER/PR, p53 and L1CAM, p53 and ER/PR and only ER/PR have the lowest DSS compare to patients with abnormal expression of; L1CAM and ER/PR, only p53 and only L1CAM (Supplementary Figure S1 B). A. B. Figure 2A-B Figure 2 A-B. A. RFS for the ESMO-ESGO-ESTRO risk groups. B. RFS for the ESMO-ESGOESTRO ‘high and advanced/metastatic’ risk group in relation to p53, L1CAM and ER/PR expression. Abbreviations: ESMO-ESGO-ESTRO, European Society for Medical Oncology - European Society of Gynaecological Oncology - European SocieTy for Radiotherapy & Oncology; p53abn, p53-abnormal; p53wt, p53wildtype; L1CAM, L1 cell-adhesion molecule; ER/PR, estrogen receptor/progesterone receptor; RFS, recurrencefree survival. Prognostic relevance of immunohistochemical expression in relation to the ESMOESGO-ESTRO risk classification Multivariate analysis was performed for the prognostic relevance of IHC expression in relation to the ESMO-ESGO-ESTRO risk classification groups. The ESMO-ESGO-ESTRO classification ‘high and advanced/metastatic’ risk was independently associated with reduced RFS (HR 3.11 [CI 1.93-5.02] P<0.001)(Table 2). P53-abn, ER/PR- and ESMO-ESGOESTRO classification ‘high and advanced/metastatic’ risk were independently associated with reduced DSS (HR 1.88 [CI 1.00-3.51] P=0.048, HR 2.74 [CI 1.48-5.07] P=0.001 and HR 5.69 [CI 3.03-10.67] P<0.001, respectively) (Table 3).
RkJQdWJsaXNoZXIy MTk4NDMw